Within a short span of just 5 years, Mynvax is recognized as a highly promising vaccine developer, thanks in part to several partnerships the Company has built to advance its vaccine development program.
The Society for Innovation and Development (SID) is focused on nurturing technology start-ups with the expert knowledge capital of IISc, to help achieve societal impact through science. ...Mynvax was incubated at the (SID) of the Indian Institute of Science, Bangalore in 2017 and operated out of its facilities until 2022. In addition to providing grant funding and access to significant streams of venture capital assistance, SID has facilitated access to various IISc facilities and enabled Mynvax to collaborate and interact with IISc investigators.
Prof. Raghavan Varadarajan, co-founder Mynvax, is a Professor at the Molecular Biophysics Unit, Indian Institute of Science. His laboratory ...has contributed significantly to the development of HIV-1 envelope protein (Env) derived vaccine formulations that have shown protective efficacy in non-human primates. Additionally, the Varadarajan laboratory was one of the first to design immunogens consisting of the conserved stem region of the viral surface protein HA that serve as building blocks towards the development of a universal influenza vaccine. Mynvax, in collaboration with the Varadarajan Laboratory, has developed novel COVID19 immunogens that have enhanced thermotolerance and improved immunogenicity relative to several clinically deployed vaccine formulations.
The Biotechnology Industry Research Assistance Council (BIRAC) is a not-for-profit public sector enterprise set up by the Department of Biotechnology (DBT), Government of India. ...In a short span, BIRAC has launched many successful schemes, networks, and initiatives that have aided in merging academic and industrial innovation. Mynvax has received financial support through grants from BIRAC under the National Biopharma Mission for the development of its novel influenza and COVID-19 vaccines.
ENDFLU is a consortium of 14 leading laboratories from India and the European Union working on development of next-generation influenza vaccine candidates ...which elicit improved protection relative to current vaccines.
Mynvax is an integral part of this consortium which consists of industry leaders and experts from Europe and India. The consortium’s members are acclaimed international influenza vaccine developers with deep scientific and technical understanding of the virus and immunological processes.
Mynvax has made a significant contribution to the consortium’s agenda with its influenza vaccine candidates, in addition to leading the manufacturing of the protein component of ENDFLU’s next-generation influenza vaccine. ENDFLU will evaluate its next-generation influenza vaccine candidate in a human challenge study in the European Union.